Andrew Johnson, MD
Ophthalmology · Cookeville, TNNPI 1184072209
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 49.5% of the total. Reporting peaked in 2023 at $7,580 and has fallen 70.4% since, to $2,244 in 2025. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $59.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$8K
- AbbVie$3K
- NEW World Medical,inc.$859
- Ivantis, Inc$750
- Genentech USA, Inc.$677
- Carl Zeiss Meditec USA, Inc.$325
- plus $2K from 23 others
What the payments were for
- Consulting fees$7,77551%
- Food & beverage$7,54149%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 20 | $7,614 |
| AbbVie(2 entities) | 102 | $2,902 |
| NEW World Medical,inc. | 16 | $859 |
| Ivantis, Inc | 4 | $750 |
| Genentech USA, Inc. | 31 | $677 |
| Carl Zeiss Meditec USA, Inc. | 4 | $325 |
| Glaukos Corporation | 2 | $310 |
| Alcon | 7 | $283 |
| Apellis Pharmaceuticals, Inc. | 9 | $233 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $172 |
| Amgen | 4 | $153 |
| Regeneron Healthcare Solutions, Inc. | 8 | $147 |
| Aerie Pharmaceuticals, Inc. | 5 | $130 |
| Tarsus Pharmaceuticals, Inc. | 5 | $123 |
| Alimera Sciences, Inc. | 6 | $101 |
| Sight Sciences, Inc. | 6 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $81 |
| Harrow Eye, LLC | 3 | $75 |
| Biotissue Holdings Inc. | 4 | $60 |
| Astellas Pharma US Inc | 2 | $53 |
| Dompe US, Inc. | 3 | $52 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Rxsight Inc | 1 | $17 |
| Sanofi | 1 | $14 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS ELITE$6,599
- DURYSTA$950
- Hydrus Microstent$644
- enVista MX60 IOL$307
- Kahook Dual Blade$211
- Clearpath$211
- Ahmed Glaucoma Valve$211
- Streamline$211
- iDoseTR$175
- CALLISTO eye$160
- MIEBO$149
- XIIDRA$149
- VYZULTA$149
- LUMERA$125
- TEPEZZA$112
- XEN GLAUCOMA TREATMENT SYSTEM$112
- AcrySof$108
How this compares
$15,389 in reported general payments places this provider in the 90th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 116 | $62,833 |
| RestasisCyclosporine | 46 | $47,609 |
| RocklatanNetarsudil Mesylat/Latanoprost | 70 | $38,880 |
| Alphagan PBrimonidine Tartrate | 71 | $31,531 |
| Fluorometholone | 324 | $19,334 |
| CombiganBrimonidine Tartrate/Timolol | 58 | $16,775 |
| Brimonidine Tartrate | 483 | $11,930 |
| Prednisolone Acetate | 343 | $11,697 |
| Cyclosporine | 23 | $10,395 |
| Latanoprost | 631 | $8,648 |
| RhopressaNetarsudil Mesylate | 13 | $7,480 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 360 | $6,676 |
| VyzultaLatanoprostene Bunod | 17 | $6,158 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $5,412 |
| Bromfenac Sodium | 42 | $4,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $2,902 | $158,747291 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $130 | $46,36083 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $7,614 | $6,15817 claims |
| AlconSimbrinza | $283 | $5,41216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Cookeville
- Michael JonesCookeville$20K
- Brittany DenaroCookeville$8K
- Alissa HudsonCookeville$5K
- Deborah ShermanNashville$3M
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian BiesmanNashville$630K
- Brian FowlerMemphis$206K
- Edward ChaumNashville$158K
- Brian JerkinsMemphis$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.